Iulian Trandafir, who a month ago reverted to the position of CEO with Farmexpert, ranking second on the domestic pharmaceutical distribution market, says he plans moderate growth this year since a too big advance would also mean a higher exposure to risk, namely to pharmacies risking insolvency.
"The target for this year is reaching turnover worth above 400m euros, against the 385m-euro level of 2010. Farmexpert has a 14% market share now. We do not target a too high increase as this would also mean rising risks," Trandafir told ZF in the first interview he had since he took over his new position.
He has a two-year contract with Farmexpert, viewed as classic for the company and "should things go well, it can be extended". About his coming back at Farmexpert, Trandafir says smiling that it is like "riding a bike. You never forget how to do it".
Iulian Trandafir, who a month ago reverted to the position of CEO with Farmexpert, ranking second on the domestic pharmaceutical distribution market, says he plans moderate growth this year since a too big advance would also mean a higher exposure to risk, namely to pharmacies risking insolvency.
"The target for this year is reaching turnover worth above 400m euros, against the 385m-euro level of 2010. Farmexpert has a 14% market share now. We do not target a too high increase as this would also mean rising risks," Trandafir told ZF in the first interview he had since he took over his new position.
He has a two-year contract with Farmexpert, viewed as classic for the company and "should things go well, it can be extended". About his coming back at Farmexpert, Trandafir says smiling that it is like "riding a bike. You never forget how to do it".
